Drugs / Sodium Nitroprusside
Sodium Nitroprusside
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | NITROPRESS | — | 1991-12-31 | fda.gov ↗ |
| Approved | US (FDA) | NIPRIDE | — | 1974-05-10 | fda.gov ↗ |
Trials 25
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT04001647 | Jun 2019 → Aug 2022 | arterial disorder, isoproterenol-mediated vasodilatation | Colorado State University | Terminated | No outcome recorded |
| Phase 0 | NCT03972683 | Apr 2019 → Jul 2021 | — | Colorado State University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03738943 | Feb 2019 → Jun 2021 | — | Colorado State University | Completed | No outcome recorded |
| Phase 0 | NCT04374500 | Jan → Oct 2006 | obesity disorder | Stefan Soderberg | Completed | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT06911372 | Aug 2025 → Apr 2027 expected | gestational diabetes | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 1 | NCT05277922 | Apr → May 2022 | isoproterenol-mediated vasodilatation | Vicore Pharma AB | Completed | No outcome recorded |
| Phase 1 | NCT01619280 | May 2012 → Jun 2013 | acute lung injury, acute respiratory distress syndrome | Mount Sinai Hospital, Canada | Unknown | No outcome recorded |
| Phase 1 | NCT02966665 | Sep 2008 → Aug 2030 expected | chronic obstructive pulmonary disease, heart failure, pulmonary arterial hypertension | D. Walter Wray | Recruiting | No outcome recorded |
| Phase 1 | NCT00690534 | Sep 2005 → Aug 2012 | muscular atrophy | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| Phase 1 | NCT00160888 | Nov 1999 → Dec 2006 | — | Heidelberg University | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03953326 | Apr 2019 → Dec 2020 | breast cancer, leukemia, lymphoma | Penn State University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 25 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT04986072 | Mar 2022 → Jun 2024 | schizoaffective disorder, schizophrenia | Beth Israel Deaconess Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02164981 | May 2015 → Mar 2017 | schizophrenia | Massachusetts General Hospital | Completed | Missed primary |
| Phase 2 | NCT01747174 | Oct 2011 → Oct 2014 | ST-elevation myocardial infarction | University Hospitals, Leicester | Completed | Missed primary |
| Phase 2 | NCT01548612 | Feb 2006 → Jun 2009 | schizophrenia | University of Sao Paulo | Completed | Met primary |
| Phase 2 | NCT00166166 | Jul 2002 → Jan 2013 | hyperlipidemia | Emory University | Terminated | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02767024 | May 2018 | symptomatic heart failure | Montefiore Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00636584 | Feb 2008 | — | Kavaklıdere Umut Hospital | Unknown | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT05525416 | Jul 2022 → Feb 2023 | — | University of Alberta | Completed | No outcome recorded |
| — | NCT05193968 | Feb 2022 → Dec 2026 expected | — | Mayo Clinic | Recruiting | No outcome recorded |
| — | NCT04928183 | Jun → Aug 2021 | isoproterenol-mediated vasodilatation | University of Alberta | Completed | No outcome recorded |
| — | NCT03317652 | Nov → Dec 2017 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| — | NCT00901719 | Apr → May 2010 | heart failure | University of Edinburgh | Completed | No outcome recorded |
| — | NCT00901888 | Apr 2009 → May 2010 | heart disorder, isoproterenol-mediated vasodilatation | University of Edinburgh | Completed | No outcome recorded |
| — | NCT02085317 | Mar 2006 → Nov 2009 | lepromatous leprosy | Curt Treu | Completed | No outcome recorded |
| Comparator or background therapy17 trials | ||||||
| Phase 1 | NCT03679780 Background | Oct 2018 → Jul 2023 | cardiovascular disorder | The University of Texas at Arlington | Completed | No outcome recorded |
| Phase 1 | NCT03680573 Background | Jan → May 2018 | cardiovascular disorder | The University of Texas at Arlington | Completed | No outcome recorded |
| Phase 1 | NCT03318094 Comparator | Oct 2017 → Nov 2026 expected | obesity disorder | Vanderbilt University Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02176044 Comparator | Aug 2014 → Feb 2016 | schizophrenia | King's College London | Completed | No outcome recorded |
| Phase 1 | NCT00891696 Comparator | Apr 2009 → Mar 2015 | muscular atrophy | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| Phase 1 | NCT00580905 Comparator | Jun 2007 → Jan 2017 | — | Vanderbilt University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00945256 Comparator | May 2003 → May 2008 | — | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| Phase 2 | NCT06424756 Background | Jul 2024 → Mar 2030 expected | — | University of Georgia | Recruiting | No outcome recorded |
| Phase 2 | NCT03446612 Background | Jan → May 2019 | anemia | GlaxoSmithKline | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02560805 Background | Oct 2015 → Mar 2027 expected | post-traumatic stress disorder | Emory University | Recruiting | No outcome recorded |
| Phase 3 | NCT00803634 Comparator | Dec 2008 → Feb 2012 | heart failure, hypertensive disorder | The Medicines Company | Completed | No outcome recorded |
| Phase 3 | NCT00093912 Comparator | Jun 2004 → Oct 2006 | hypertensive disorder | The Medicines Company | Completed | No outcome recorded |
| Phase 4 | NCT03743103 Background | Apr 2019 → Oct 2021 | intracerebral hemorrhage | Cristália Produtos Químicos Farmacêuticos Ltda. | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01333891 Comparator | Dec 2012 | — | Medical University of Vienna | Terminated | No outcome recorded |
| — | NCT01048125 Background | Aug 2009 → Jul 2012 | cardiomyopathy | University of Missouri-Columbia | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00253929 Background | Nov 2005 → Feb 2006 | — | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00810381 Comparator | Jan → Jun 1999 | glaucoma | Medical University of Vienna | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 46 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium Nitroprusside | “This study was designed with the objective of evaluating the beneficial effects of combining esmolol hydrochloride with sodium nitroprusside for the blood pressure control of...” NCT03743103 ↗41“After a baseline period, all three sites will undergo tests of blood vessel function including an acetylcholine dose-response protocol and a test of maximal skin blood flow...” NCT06911372 ↗ “Sodium nitroprusside (100 µg) will be infused intravenously as a bolus, followed 60 seconds later by a bolus of phenylephrine hydrochloride (150 µg).” NCT01048125 ↗ “sodium nitroprusside (endothelium-independent vasodilator) at 2, 4 and 8 µg/min” NCT04374500 ↗ “sodium nitroprusside” NCT00803634 ↗ |
| Known as | Nipride | “After Ach, SNP (Nipride® 10mg/ml - Biolab, São Paulo, Brazil) was delivered by 7 iontophoretic pulses of 0.2 mA for 20 s with 180 s interval between pulses using another drug...” NCT02085317 ↗ |
| Known as | Nipruss | “Sodium-Nitroprusside: (Nipruss, Sanol-Schwarz, Monheim, Germany):” NCT00810381 ↗ |
| Known as | SNP | “After Ach, SNP (Nipride® 10mg/ml - Biolab, São Paulo, Brazil) was delivered by 7 iontophoretic pulses of 0.2 mA for 20 s with 180 s interval between pulses using another drug...” NCT02085317 ↗5“low-intensity resistance exercise with sodium nitroprusside (SNP), a pharmacological vasodilator infusion into the femoral artery immediately after exercise to simulate the...” PMID 22362401 ↗ Feb 2012 “A prior pilot investigation suggested that adjunctive sodium nitroprusside (SNP) administered intravenously had rapid efficacy in the treatment of patients with schizophrenia.” PMID 30916714 ↗ Jul 2019 “Muscle protein kinetics were measured in the basal state and during a 180 min infusion of sodium nitroprusside (SNP) and amino acids (Premsol 10%) (SNP+AA).” NCT00945256 ↗ “Sodium nitroprusside (SNP) has been reported to rapidly reduce psychotic symptoms in patients with schizophrenia.” PMID 27655012 ↗ Sep 2016 “insulin plus sodium nitroprusside (SNP) at variable rate to double leg blood flow” PMID 20724580 ↗ Aug 2010 |
| Action | Activate | “Sodium nitroprusside is a short-acting, potent vasodilator that activates guanylate cyclase directly or by production of nitric oxide” NCT03317652 ↗ |
| Route | Intravenous | “was administered intravenously as per institutional practice” NCT00093912 ↗ |